Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catasys Inc (CATS)

Catasys Inc (CATS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 229,370
  • Shares Outstanding, K 16,585
  • Annual Sales, $ 15,180 K
  • Annual Income, $ -14,210 K
  • 60-Month Beta 1.65
  • Price/Sales 15.79
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.34
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -14.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.69 +1.61%
on 10/17/19
18.50 -24.81%
on 09/24/19
-3.30 (-19.17%)
since 09/17/19
3-Month
12.89 +7.91%
on 08/27/19
19.26 -27.76%
on 07/18/19
-5.10 (-26.83%)
since 07/17/19
52-Week
7.51 +85.22%
on 10/26/18
20.83 -33.22%
on 05/20/19
+4.25 (+44.00%)
since 10/17/18

Most Recent Stories

More News
Catasys Announces $45 Million Debt Financing Commitment from Goldman Sachs to Support Accelerating Growth

Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, has entered into a financing agreement with Goldman Sachs Specialty Lending Group, L.P....

CATSD : 10.0000 (+12.61%)
CATS : 13.93 (+0.72%)
Catasys to Participate in 4th Annual Dougherty & Company Institutional Investor Conference

Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced that Mr. Terren Peizer, the Company's Chairman and CEO, is scheduled to...

CATSD : 10.0000 (+12.61%)
CATS : 13.93 (+0.72%)
Catasys Reports 2019 Second Quarter Financial Results

Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today reported its financial results for the second quarter ended June 30, 2019. The Company...

CATSD : 10.0000 (+12.61%)
CATS : 13.93 (+0.72%)
Catasys Expands Partnership with Leading National Health Plan

Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced the expansion of its OnTrak-A solution with a leading national health...

CATSD : 10.0000 (+12.61%)
CATS : 13.93 (+0.72%)
Catasys Schedules 2019 Second Quarter Financial Results Conference Call for August 14, 2019

Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its second quarter...

CATSD : 10.0000 (+12.61%)
CATS : 13.93 (+0.72%)
BriaCell Appoints Richard J. Berman to Board of Directors

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced...

IMRN : 3.27 (-2.39%)
BCT.VN : 0.040 (unch)
BCTXF : 0.0300 (unch)
ADXS : 0.32 (+3.23%)
CYRX : 14.66 (+3.09%)
BIVI : 0.0420 (-16.00%)
CATS : 13.93 (+0.72%)
MRK : 83.94 (-0.60%)
INCY : 77.84 (-0.36%)
Analysts Estimate Catasys (CATS) to Report a Decline in Earnings: What to Look Out for

Catasys (CATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CATS : 13.93 (+0.72%)
Catasys to Present at the Canaccord Genuity 39th Annual Growth Conference

Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced that Mr. Terren Peizer, the Company's Chairman and CEO, is scheduled to...

CATSD : 10.0000 (+12.61%)
CATS : 13.93 (+0.72%)
Catasys Launches Breakthrough AI Capability to Address Chronic Disease

Catasys, Inc. (NASDAQ:CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced Catasys PRE(TM) (Predict-Recommend-Engage).

CATSD : 10.0000 (+12.61%)
CATS : 13.93 (+0.72%)
Catasys Appoints Industry Veteran Rob Rebak to Board of Directors

Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced the appointment of Mr. Robert L. Rebak to its Board of Directors, replacing...

CATSD : 10.0000 (+12.61%)
CATS : 13.93 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CATS with:

Business Summary

Catasys, Inc., formerly known as Hythiam, Inc., provides specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Company's program seeks to improve member health by delivering medical and psychosocial...

See More

Key Turning Points

2nd Resistance Point 14.72
1st Resistance Point 14.27
Last Price 13.93
1st Support Level 13.54
2nd Support Level 13.26

See More

52-Week High 20.83
Fibonacci 61.8% 15.74
Fibonacci 50% 14.17
Last Price 13.93
Fibonacci 38.2% 12.60
52-Week Low 7.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar